Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:administeredBy |
oral
|
| gptkbp:alternativeName |
ipatasertib
|
| gptkbp:CASNumber |
1001264-89-6
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:Genentech
|
| gptkbp:hasMolecularFormula |
C24H28N6O2
|
| gptkbp:hasSMILES |
CC1=CC(=O)N(C2=NC=NC(=C2N1)N3CCN(CC3)C4=CC=CC=C4)C
|
| https://www.w3.org/2000/01/rdf-schema#label |
GDC-0068
|
| gptkbp:indication |
gptkb:cancer
|
| gptkbp:IUPACName |
N-{4-[1-(2,3-dihydro-1H-inden-5-yl)-3-methyl-1H-pyrazol-5-yl]pyrimidin-2-yl}-N-methylacetamide
|
| gptkbp:mechanismOfAction |
AKT inhibitor
|
| gptkbp:molecularWeight |
432.52 g/mol
|
| gptkbp:PubChem_CID |
25154816
CHEMBL2105726 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:target |
gptkb:AKT1
gptkb:AKT2 gptkb:AKT3 |
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:bfsParent |
gptkb:Ipatasertib
|
| gptkbp:bfsLayer |
7
|